Product image of Ivabradin Beta (Ivabradine Hydrochloride) supplied by GNH India

Ivabradin Beta

Active Ingredient:
Ivabradine Hydrochloride
Origin:
EU

Ivabradin Beta (Ivabradine Hydrochloride)

Ivabradine, the active ingredient in Ivabradin Beta, is a If channel inhibitor presented as a tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction in adults.
GNH India supplies Ivabradin Beta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Betapharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ivabradine is used in cardiovascular conditions that benefit from selective heart‑rate reduction.
  • Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance.
  • Heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, enhancing functional capacity and decreasing hospitalisations.
  • Elevated resting heart rate despite beta‑blocker therapy: provides additional rate control without affecting contractility.

How It Works

  • Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows spontaneous depolarisation. By reducing the pacemaker activity, the drug lowers heart rate while preserving myocardial contractility and blood pressure, thereby decreasing myocardial oxygen demand in angina and improving haemodynamic efficiency in heart failure.

Side Effects

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate‑lowering action or visual pathways.

Common Side Effects

  • Luminous phenomena (phosphenes) or transient visual disturbances.
  • Headache.
  • Dizziness or light‑headedness.
  • Nausea.
  • Fatigue.

Serious or Rare Side Effects

  • Severe bradycardia requiring medical attention.
  • Atrial fibrillation or other arrhythmias.
  • Symptomatic hypotension.
  • Visual loss or persistent visual impairment.
  • Allergic reactions such as rash or angioedema.
  • Hepatic dysfunction indicated by abnormal liver enzymes.

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential risks.
  • Cardiovascular assessment: confirm baseline heart rate and rhythm.
  • Heart‑rate monitoring: check regularly, especially after dose adjustments.
  • Avoid in severe hepatic impairment: dose reduction may be required.
  • Caution with concomitant beta‑blockers or other bradycardic agents.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at room temperature: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Ivabradine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
  • Other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction.
  • Calcium‑channel blockers affecting AV conduction (verapamil, diltiazem).

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (rifampin, carbamazepine): may reduce effectiveness.

  • Diuretics causing electrolyte imbalance: monitor for arrhythmias.
  • Antihypertensive agents: observe blood pressure and heart‑rate response.

Frequently Asked Questions

Ivabradin Beta contains ivabradine, which is prescribed for chronic stable angina and for heart failure with reduced ejection fraction (NYHA class II‑III). It helps lower heart rate, reducing chest pain episodes and improving functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, slowing the pacemaker activity. This reduces heart rate without decreasing contractility, lowering myocardial oxygen demand in angina and improving haemodynamic efficiency in heart failure.

The dosage of Ivabradin Beta is determined by the prescribing clinician based on the patient’s clinical status, heart‑rate targets, and tolerability. The prescriber will adjust the dose according to therapeutic response and safety monitoring.

Safety of ivabradine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractility, making ivabradine a useful adjunct when additional rate control is needed.

Ivabradin Beta should be stored at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Ivabradin Beta is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced to maintain consistent plasma levels as directed by the prescriber.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to persistent visual loss. Patients should be monitored for these events, especially during dose initiation and titration.

Ivabradin Beta is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or a resting heart rate below 50 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine or any excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT